A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Document Type
Article
Abstract
BACKGROUND:: Bapineuzumab, a humanized anti-amyloid-beta (Aβ) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD. METHODS:: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received 6 infusions, 13 weeks apart, with final assessments at week 78. The prespecified primary efficacy analysis in the modified intent-to-treat population assumed linear decline and compared treatment differences within dose cohorts on the Alzheimer's Disease Assessment Scale-Cognitive and Disability Assessment for Dementia. Exploratory analyses combined dose cohorts and did not assume a specific pattern of decline. RESULTS:: No significant differences were found in the primary efficacy analysis. Exploratory analyses showed potential treatment differences (p < 0.05, unadjusted for multiple comparisons) on cognitive and functional endpoints in study "completers" and APOE ε4 noncarriers. Reversible vasogenic edema, detected on brain MRI in 12/124 (9.7%) bapineuzumab-treated patients, was more frequent in higher dose groups and APOE ε4 carriers. Six vasogenic edema patients were asymptomatic; 6 experienced transient symptoms. CONCLUSIONS:: Primary efficacy outcomes in this phase 2 trial were not significant. Potential treatment differences in the exploratory analyses support further investigation of bapineuzumab in phase 3 with special attention to APOE ε4 carrier status. CLASSIFICATION OF EVIDENCE:: Due to varying doses and a lack of statistical precision, this Class II ascending dose trial provides insufficient evidence to support or refute a benefit of bapineuzumab. © 2009 by AAN Enterprises, Inc.
Publication Date
1-1-2009
Publication Title
Neurology
ISSN
00283878
E-ISSN
1526632X
Volume
73
Issue
24
First Page
2061
Last Page
2070
PubMed ID
19923550
Digital Object Identifier (DOI)
10.1212/WNL.0b013e3181c67808
Recommended Citation
Salloway, S.; Sperling, R.; Gilman, S.; Fox, N. C.; Blennow, K.; Raskind, M.; Sabbagh, M.; Honig, L. S.; Doody, R.; Van Dyck, C. H.; Mulnard, R.; Barakos, J.; Gregg, K. M.; Liu, E.; Lieberburg, I.; Schenk, D.; Black, R.; and Grundman, M., "A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease" (2009). Neurology. 727.
https://scholar.barrowneuro.org/neurology/727